CanariaBio CEO Buys Company Shares... "Practicing Responsible Management"
[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 7th that CEO Nahanik purchased 52,000 shares of the company's stock on the open market. The total purchase amount is 1 billion KRW. This stock repurchase is interpreted as a demonstration of confidence in the upcoming global Phase 3 clinical trial of Oregovomab and a commitment to stock price management.
A representative from Canaria Bio stated, "Recently, the stock price plummeted due to baseless fake news such as 'delisting,' 'breach of trust,' and 'embezzlement,' leading us to believe the stock is undervalued compared to its fundamentals, which is why we proceeded with the stock repurchase. We will strongly take legal action against those who spread fake news that damages our shareholder value in the future."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Recently, Canaria Bio has been actively recruiting patients for the global Phase 3 clinical trial of Oregovomab across 16 countries and approximately 152 sites. The recruitment has surpassed 60% of the target 602 patients, and efforts are being intensified by adding clinical sites in India. Accordingly, the interim results are expected to be announced in the third quarter of next year as originally planned.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
